June 2019 Shareholder and Stakeholder Letter

Dear Shareholders and Stakeholders,

As we approach the end of the 2nd Quarter, I wanted to provide an update on our business and our planned endeavors for 3Q19. Overall, our executive team is working diligently to make sure the promise of Alitair remains alive and that our firm remains very investable. Our target markets, our pipeline, our intellectual property, our clinical development and our regulatory strategy all remains very viable. And, the long-term opportunity to capture increasing value for shareholders and stakeholders is exciting.

Read More
Year End 2018 Shareholder Letter

Now that 2018 has ended, I would like to provide an update to our external shareholders and stakeholders. First, I would like to reaffirm that the potential of the Alitair pipeline remains strong and relevant in terms of meeting unmet medical needs. Our valuation has held firm. And, helping treat respiratory disease and providing solutions for the Opioid Crisis are central to our mission.

Read More
Alitair Pharmaceuticals
3rd Quarter 2018 Shareholder Letter

Dear Valued Alitair Shareholder,

I want to provide you with a brief update on Alitair Pharmaceuticals.

Critical Need for More Capital

Alitair requires additional capital to fund its 24-month Clinical Development Plan and for General Corporate Purposes. I am limited to what I can say as Alitair is working through the final steps of a closing process to raise capital with two funding sources -- one a new investment fund that targets Alternate Investment from endowment funds from major non-profit health systems and the other a Healthcare Investment Bank. Together, these two entities will provide new capital to help grow our company.

Read More
Alitair Pharmaceuticals
Alitair now on Facebook

Alitair launches a Facebook page — focused on biopharma news and information relevant to the therapeutics areas of our medicines. This includes bronchiectasis, cough, and providing solutions for the abuse and misuse of prescription drugs. You can find the Alitair Facebook page at www.facebook.com/alitairpharma. Please “Like” and “Follow” our Alitair Facebook page.

Read More
Alitair Presents at National Investment Banking Association Meeting in New York City (Click for Video)

Alitair Pharmaceuticals CEO, James Hoyes, presents the corporate overview and strategic direction during the National Investment Banking Association (NIBA) Meeting in NYC. The meeting ran February 27-28, 2017.

Mr. Hoyes focused on the proprietary ion-exchange resin formulation technology that supports the highly innovative Overdose Reduction technology and forms the basis of its non-narcotic and narcotic prescription cough medicines portfolio. The Overdose Reduction technology, called ODR, may serve as a significant product in the fight against the Opioid Crisis. ODR serves to minimize the risk of overdose due to the abuse and/or misuse of prescription medicines especially opioids and benzodiazepines. Mr. Hoyes also reviewed the portfolio of Orphan Drugs focused on the rare pulmonary disease called bronchiectasis.

Read More
Alitair Pharmaceuticals